^
    Back
    Association details:
    Biomarker:PYCR1 underexpression
    Cancer:Renal Cell Carcinoma
    Drug Class:Immunotherapy +
    Tyrosine kinase inhibitor
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Neoplasia
    Title:

    Effects of PYCR1 on prognosis and immunotherapy plus tyrosine kinase inhibition responsiveness in metastatic renal cell carcinoma patients

    Published date:
    07/30/2023
    Excerpt:
    Patients in the low-PYCR1 group had greater objective response rate (52.2% vs 18.2%) and longer PFS in both cohorts (ZS-MRCC cohort, P=0.01, HR=2.80; JAVELIN-101 cohort, P<0.001, HR=1.85).
    DOI:
    10.1016/j.neo.2023.100919